Medivation Inc. and Astellas Pharma Inc. on Sept. 13 announced the availability of XTANDI (enzalutamide) capsules for patients in the United States with metastatic castration-resistant prostate cancer.
XTANDI was approved by the U.S. Food and Drug Administration on Aug. 31.
“We are proud of our accelerated efforts to get this new treatment option to patients with metastatic castration-resistant prostate cancer who have previously received docetaxel,” said David Hung, president and chief executive officer of Medivation.
XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
Astellas and Medivation also announced a patient support program, called XTANDI Access Services, that will provide access and reimbursement support to physicians and patients and assist eligible patients without insurance.
- « Prev
- Next »